Literature DB >> 21245074

Quantifying the economic burden of productivity loss in rheumatoid arthritis.

Ivana Filipovic1, David Walker, Fiona Forster, Alistair S Curry.   

Abstract

OBJECTIVE: In light of the large number of recent studies and systematic reviews investigating the cost of RA, this article examines the methods used to assess the impact of RA on employment and work productivity, and provides an overview of the issues surrounding work productivity loss in the RA population.
METHODS: A review of the published literature was conducted in order to identify relevant articles. These articles were then reviewed and their methodologies compared. The various methods used to calculate economic loss were then explained and discussed.
RESULTS: We found that although methods of lost productivity and associated costs varied between studies, all suggest that RA is associated with significant burden of illness. Economic analyses that exclude indirect costs will therefore underestimate the full economic impact of RA. However, the methods used to calculate productivity loss have a significant impact on the results of indirect cost analyses, and should be selected carefully when designing such studies. Several factors relating to the disease, the job and socio-demographics have been found to predict work disability.
CONCLUSIONS: Consideration of these factors is vital when measuring the extent of both absenteeism and presenteeism, and will allow for more accurate estimation of the impact of RA on work productivity. This information may also guide interventions aiming to prevent or postpone work disability and job loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245074     DOI: 10.1093/rheumatology/keq399

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  20 in total

1.  Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.

Authors:  Christopher B Atzinger; Jeff J Guo
Journal:  Am Health Drug Benefits       Date:  2017-02

2.  Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.

Authors:  Katrine Løppenthin; Bente Appel Esbensen; Mikkel Østergaard; Rikke Ibsen; Jakob Kjellberg; Poul Jennum
Journal:  Clin Rheumatol       Date:  2016-10-25       Impact factor: 2.980

Review 3.  Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.

Authors:  Rafael Alfonso-Cristancho; Nigel Armstrong; Ramesh Arjunji; Rob Riemsma; Gill Worthy; Rita Ganguly; Jos Kleijnen
Journal:  Clin Rheumatol       Date:  2016-10-10       Impact factor: 2.980

4.  Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis.

Authors:  Kavita Nair; Vahram Ghushchyan; Ahmad Naim
Journal:  Am Health Drug Benefits       Date:  2013-03

5.  Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Authors:  Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos
Journal:  Eur J Health Econ       Date:  2014-05-16

6.  Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database.

Authors:  Bruce C M Wang; Ping-Ning Hsu; Wesley Furnback; John Ney; Ya-Wen Yang; Chi-Hui Fang; Chao-Hsiun Tang
Journal:  Drugs Real World Outcomes       Date:  2016-03

7.  Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group.

Authors:  Chantelle Murley; Petter Tinghög; Kristina Alexanderson; Jan Hillert; Emilie Friberg; Korinna Karampampa
Journal:  Pharmacoeconomics       Date:  2021-05-10       Impact factor: 4.981

8.  Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.

Authors:  Ari Gnanasakthy; Sandra Lewis; Marci Clark; Margaret Mordin; Carla DeMuro
Journal:  Health Qual Life Outcomes       Date:  2013-05-15       Impact factor: 3.186

9.  Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Authors:  Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Nobuyuki Miyasaka; Masaya Mukai; Tsukasa Matsubara; Shoji Uchida; Hideto Akama; Hartmut Kupper; Vipin Arora; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2013-01-11       Impact factor: 19.103

10.  Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.

Authors:  Josef S Smolen; Vibeke Strand; Andrew S Koenig; Annette Szumski; Sameer Kotak; Thomas V Jones
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.